• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部鳞状细胞癌中人类白细胞抗原I类等位基因和单倍型缺失:临床及免疫遗传学后果

Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.

作者信息

Grandis J R, Falkner D M, Melhem M F, Gooding W E, Drenning S D, Morel P A

机构信息

Department of Otolaryngology and Pharmacology, University of Pittsburgh, Pennsylvania 15213, USA.

出版信息

Clin Cancer Res. 2000 Jul;6(7):2794-802.

PMID:10914726
Abstract

The expression of human leukocyte antigen (HLA) class I molecules on the cell surface is necessary for the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system. Down-regulation of HLA class I gene expression has been implicated in tumorigenesis, including squamous cell carcinoma of the head and neck (SCCHN). Loss of MHC class I antigens may be one mechanism by which tumor cells escape immune detection. We performed prospective immunostaining of 26 primary SCCHN tumors and samples of normal mucosa harvested several centimeters away from the primary tumor, using a large panel of antibodies directed against allele-specific as well as monomorphic determinants of HLA class I molecules. Loss of expression of HLA class I proteins in the tumor was found in 50% (13 of 26) of primary tumors and was highly correlated with HLA loss in the corresponding normal mucosa (P < 0.0001). Further analysis demonstrated that the loss of HLA class I expression in the tumor was significantly associated with regional lymph node metastases (nodal stage; P = 0.0388), and that the number of HLA class I alleles lost in the normal mucosa was associated with subsequent development of a new primary aerodigestive tract cancer (P = 0.042). A patient with two metachronous cancers available for analysis had no evidence of HLA loss in the first tumor, demonstrated allelic loss in the second cancer, and subsequently died of disease. These results suggest that the loss of expression of HLA class I alleles may have prognostic implications.

摘要

细胞表面人类白细胞抗原(HLA)I类分子的表达对于将肽抗原呈递给免疫系统的细胞毒性CD8 + T淋巴细胞是必需的。HLA I类基因表达的下调与肿瘤发生有关,包括头颈部鳞状细胞癌(SCCHN)。MHC I类抗原的缺失可能是肿瘤细胞逃避免疫检测的一种机制。我们使用一大组针对HLA I类分子等位基因特异性以及单态性决定簇的抗体,对26例原发性SCCHN肿瘤和从原发性肿瘤几厘米外采集的正常黏膜样本进行了前瞻性免疫染色。在50%(26例中的13例)的原发性肿瘤中发现肿瘤中HLA I类蛋白表达缺失,并且与相应正常黏膜中的HLA缺失高度相关(P < 0.0001)。进一步分析表明,肿瘤中HLA I类表达的缺失与区域淋巴结转移(淋巴结分期;P = 0.0388)显著相关,并且正常黏膜中丢失的HLA I类等位基因数量与随后发生的新的原发性气消化道癌症相关(P = 0.042)。一名有两个异时性癌症可供分析的患者,在第一个肿瘤中没有HLA缺失的证据,在第二个癌症中出现等位基因缺失,随后死于该疾病。这些结果表明,HLA I类等位基因表达的缺失可能具有预后意义。

相似文献

1
Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.头颈部鳞状细胞癌中人类白细胞抗原I类等位基因和单倍型缺失:临床及免疫遗传学后果
Clin Cancer Res. 2000 Jul;6(7):2794-802.
2
Human monoclonal antibodies as a tool for the detection of HLA class I allele-specific expression loss in head-and-neck squamous cell carcinoma and corresponding lymph node metastases.人单克隆抗体作为检测头颈部鳞状细胞癌及相应淋巴结转移中HLA I类等位基因特异性表达缺失的工具。
Hum Immunol. 2006 Sep;67(9):692-9. doi: 10.1016/j.humimm.2006.06.001. Epub 2006 Jul 14.
3
High level of aneuploidy of chromosome 6 by FISH analysis of head and neck squamous cell carcinoma: limited applicability of LOH analysis to define HLA loss.通过对头颈部鳞状细胞癌进行荧光原位杂交(FISH)分析发现6号染色体非整倍体水平较高:杂合性缺失(LOH)分析在定义HLA缺失方面的适用性有限。
Hum Immunol. 2004 Dec;65(12):1455-62. doi: 10.1016/j.humimm.2004.06.012.
4
Loss of heterozygosity at 6p21 underlying [corrected] HLA class I downregulation in Chinese primary esophageal squamous cell carcinomas.中国原发性食管鳞状细胞癌中6p21杂合性缺失导致[校正后] HLA I类下调
Tissue Antigens. 2008 Aug;72(2):105-14. doi: 10.1111/j.1399-0039.2008.01078.x.
5
Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance.转移性宫颈癌细胞改变HLA表达作为免疫监视受损的一个因素。
Gynecol Oncol. 1995 Jun;57(3):366-75. doi: 10.1006/gyno.1995.1156.
6
Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.人乳头瘤病毒16型E7特异性T细胞对头颈部病毒感染性鳞状细胞癌的抗肿瘤活性
Cancer Res. 2005 Dec 1;65(23):11146-55. doi: 10.1158/0008-5472.CAN-05-0772.
7
MHC-class I antigen expression on micrometastases in bone marrow of patients with head and neck squamous cell cancer.头颈部鳞状细胞癌患者骨髓微转移灶上的MHC I类抗原表达
Anticancer Res. 2003 Mar-Apr;23(2B):1467-71.
8
Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma.扁桃体鳞状细胞癌中抗原加工机制及生存素表达的特征分析
Cancer. 2003 May 1;97(9):2203-11. doi: 10.1002/cncr.11311.
9
Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.手术切除的黑色素瘤病灶中选择性单态性和多态性HLA I类抗原决定簇缺失
Tissue Antigens. 2005 May;65(5):419-28. doi: 10.1111/j.1399-0039.2005.00381.x.
10
Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.原发性上颌窦鳞状细胞癌病变中塔帕辛与HLA I类抗原下调的关联与患者生存率降低相关。
Clin Cancer Res. 2003 Sep 15;9(11):4043-51.

引用本文的文献

1
Immunotherapy in Head and Neck Cancer.头颈部癌症的免疫疗法
Cancer Treat Res. 2025;129:119-156. doi: 10.1007/978-3-031-97242-3_7.
2
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.托瑞帕利单抗联合化疗作为广泛期小细胞肺癌的一线治疗:3期EXTENTORCH随机临床试验
JAMA Oncol. 2025 Jan 1;11(1):16-25. doi: 10.1001/jamaoncol.2024.5019.
3
Immune Escape Strategies in Head and Neck Cancer: Evade, Resist, Inhibit, Recruit.头颈癌中的免疫逃逸策略:逃避、抵抗、抑制、招募。
Cancers (Basel). 2024 Jan 11;16(2):312. doi: 10.3390/cancers16020312.
4
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.对头颈部癌肿瘤微环境进行开发和治疗性调控以改善临床结局。
Front Oral Health. 2022 Jul 22;3:902160. doi: 10.3389/froh.2022.902160. eCollection 2022.
5
The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.肿瘤微环境中的癌症免疫逃逸机制与药物干预
Front Pharmacol. 2022 May 24;13:868695. doi: 10.3389/fphar.2022.868695. eCollection 2022.
6
Signature Based on Six Autophagy-related Genes to Predict Prognosis of Head and Neck Squamous Cell Carcinoma.基于六个自噬相关基因的signature 预测头颈部鳞状细胞癌的预后。
Curr Med Sci. 2022 Jun;42(3):597-605. doi: 10.1007/s11596-022-2560-1. Epub 2022 Jun 1.
7
Major histocompatibility complex class I molecule expression by pancreatic cancer cells is regulated by activation and inhibition of the epidermal growth factor receptor.胰腺癌细胞主要组织相容性复合体 I 类分子的表达受表皮生长因子受体的激活和抑制调节。
Immunol Res. 2022 Jun;70(3):371-391. doi: 10.1007/s12026-022-09262-3. Epub 2022 Mar 18.
8
Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.头颈部鳞状细胞癌中的免疫荒漠:肿瘤免疫微环境调节的挑战与机遇综述。
Oral Oncol. 2021 Sep;120:105420. doi: 10.1016/j.oraloncology.2021.105420. Epub 2021 Jul 1.
9
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.通过 MHC I 类抗原呈递丧失实现癌症免疫逃逸。
Front Immunol. 2021 Mar 9;12:636568. doi: 10.3389/fimmu.2021.636568. eCollection 2021.
10
Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials.将放化疗与免疫治疗联合应用于头颈部鳞状细胞癌的根治性治疗:当前临床试验综述。
Radiol Oncol. 2020 Oct 11;54(4):377-393. doi: 10.2478/raon-2020-0060.